+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Brain Ischemia - Pipeline Review, H2 2015

  • ID: 3500395
  • Report
  • October 2015
  • 66 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CohBar Inc.
  • NeuroNascent, Inc.
  • NeurOp, Inc
  • Prolong Pharmaceuticals
  • Sylentis S.A.
  • Vect-Horus S.A.S
  • MORE
Brain Ischemia - Pipeline Review, H2 2015

Summary

The report ‘Brain Ischemia - Pipeline Review, H2 2015’, provides an overview of the Brain Ischemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Ischemia and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Brain Ischemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Brain Ischemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Brain Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Brain Ischemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Brain Ischemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Brain Ischemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • CohBar Inc.
  • NeuroNascent, Inc.
  • NeurOp, Inc
  • Prolong Pharmaceuticals
  • Sylentis S.A.
  • Vect-Horus S.A.S
  • MORE
List of Tables

List of Figures

Introduction

REPORT COVERAGE

Brain Ischemia Overview

Therapeutics Development

Pipeline Products for Brain Ischemia - Overview

Pipeline Products for Brain Ischemia - Comparative Analysis

Brain Ischemia - Therapeutics under Development by Companies

Brain Ischemia - Therapeutics under Investigation by Universities/Institutes

Brain Ischemia - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Brain Ischemia - Products under Development by Companies

Brain Ischemia - Products under Investigation by Universities/Institutes

Brain Ischemia - Companies Involved in Therapeutics Development

CohBar Inc.

Immune Pharmaceuticals Inc.

Lixte Biotechnology Holdings, Inc.

NeuroNascent, Inc.

NeurOp, Inc

Prolong Pharmaceuticals

Spectrum Pharmaceuticals, Inc.

Sylentis S.A.

The International Biotechnology Center (IBC) Generium

Vect-Horus S.A.S

Brain Ischemia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AB-002 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

F-573 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GNR-014 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Humanin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LAU-0901 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LB-100 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LB-102 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NP-10679 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

phycocyanobilin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Sanguinate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Brain Ischemia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Antagonize Gpr17 for Brain Ischemia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SPI-1620 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stem Cell Therapy for Ischemia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptide for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VHN-439 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Brain Ischemia - Recent Pipeline Updates

Brain Ischemia - Dormant Projects

Brain Ischemia - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Brain Ischemia, H2 2015

Number of Products under Development for Brain Ischemia - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Brain Ischemia - Pipeline by CohBar Inc., H2 2015

Brain Ischemia - Pipeline by Immune Pharmaceuticals Inc., H2 2015

Brain Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015

Brain Ischemia - Pipeline by NeuroNascent, Inc., H2 2015

Brain Ischemia - Pipeline by NeurOp, Inc, H2 2015

Brain Ischemia - Pipeline by Prolong Pharmaceuticals, H2 2015

Brain Ischemia - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015

Brain Ischemia - Pipeline by Sylentis S.A., H2 2015

Brain Ischemia - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015

Brain Ischemia - Pipeline by Vect-Horus S.A.S , H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Brain Ischemia Therapeutics - Recent Pipeline Updates, H2 2015

Brain Ischemia - Dormant Projects, H2 2015

Brain Ischemia - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Brain Ischemia, H2 2015

Number of Products under Development for Brain Ischemia - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015
Note: Product cover images may vary from those shown
4 of 5
CohBar Inc.
Immune Pharmaceuticals Inc.
Lixte Biotechnology Holdings, Inc.
NeuroNascent, Inc.
NeurOp, Inc
Prolong Pharmaceuticals
Spectrum Pharmaceuticals, Inc.
Sylentis S.A.
The International Biotechnology Center (IBC) Generium
Vect-Horus S.A.S
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll